RCKT - Rocket Pharmaceuticals Inc Stock Price, Fair Value and News

$13.04-0.12 (-0.91%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RCKT Price Action

Last 7 days

-16.8%

Last 30 days

-26.0%

Last 90 days

-29.5%

Trailing 12 Months

-40.4%

RCKT RSI Chart

RCKT Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-4.61

Price/Sales (Trailing)

159.26

Price/Free Cashflow

-5.88

RCKT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RCKT Fundamentals

RCKT Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

-22.85%

Rev. Growth (Qtr)

-42.15%

RCKT Earnings

Earnings (TTM)

-258.1M

Earnings Growth (Yr)

-7.79%

Earnings Growth (Qtr)

4.2%

RCKT Profitability

Return on Equity

-78.26%

Return on Assets

-65.55%

Free Cashflow Yield

-17.02%

RCKT Investor Care

Shares Dilution (1Y)

1.11%

Diluted EPS (TTM)

-2.73

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.4M	7.9M	7.5M	0
2023	5.2M	5.4M	5.7M	5.3M
2022	2.8M	2.9M	3.5M	3.9M
2021	2.1M	2.2M	2.5M	3.1M
2020	3.8M	3.2M	2.8M	2.2M
2019	2.0M	2.5M	3.1M	3.4M
2018	0	0	0	1.7M
2017	0	0	0	0
2016	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones EnergÃƒÆ’Ã‚Â©ticas, Medioambientales y TecnolÃƒÆ’Ã‚Â³gicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

CEO	Dr. Gaurav D. Shah M.D.
WEBSITE	https://rocketpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	240

Rocket Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rocket Pharmaceuticals Inc? What does RCKT stand for in stocks?

RCKT is the stock ticker symbol of Rocket Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rocket Pharmaceuticals Inc (RCKT)?

As of Wed Nov 20 2024, market cap of Rocket Pharmaceuticals Inc is 1.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RCKT stock?

You can check RCKT's fair value in chart for subscribers.

Is Rocket Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RCKT is over valued or under valued. Whether Rocket Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rocket Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RCKT.

What is Rocket Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, RCKT's PE ratio (Price to Earnings) is -4.61 and Price to Sales (PS) ratio is 159.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCKT PE ratio will change depending on the future growth rate expectations of investors.